Finding Cancer Genes.

Slides:



Advertisements
Similar presentations
I’ve just been diagnosed with CML. Could you answer my questions?
Advertisements

Leukemia is characterized by hyperproliferation of immature white blood cells white blood cell Leukemic patientnormal person red blood cells hyperproliferation.
Theories of cancer genesis
PDGF β Receptor. Protein 1106 amino acid protein Weinberg Fig 5.10.
MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.
Molecular Medicine. Focus on Cancer Most chemotherapies were developed before the human genome was sequenced Many are alkylating agents that attach methyl.
Oncogenes and Chromosomal Aberrations The Story of Abl and the Philadelphia Chromosome.
Rakesh Biswas MD Professor, Medicine, People's College of Medical Sciences, Bhopal, India Lecture first conceived and delivered to medicine undergrads.
Chronic myeloid leukaemia. THE STORY OF CHRONIC MYELOID LEUKAEMIA ‘It is moreover, the same conclusion which Bennett came to in the much-discussed matter.
Marty O’Neill II Carmen Banea
Products of haematopoiesis. Leukaemia, the current hypothesis Defect in maturation of white blood cells-may involve a block in differentiation and/or.
HIC1 attenuates Wnt signaling by recruitment TCF-4 and β-catenin to the nuclear bodies EMBO Journal (2006)

Leukemia is characterized by hyperproliferation of immature white blood cells white blood cell Leukemic patientnormal person red blood cells hyperproliferation.
Chapter 4 Cellular Oncogenes ~ Mar 22, 2007.
From Signal Transduction to Targeted Therapy (Fall 2010) Pin Ling ( 凌 斌 ), Ph.D. Department of Microbiology & Immunology, NCKU ext 5632
Normal haemopoiesis. ABNORMALITIES IN THE HEMOPOIETIC SYSTEM CAN LEAD TO HEMOGLOBINOPATHIES HEMOPHILIA DEFECTS IN HEMOSTASIS/THROMBOSIS HEMATOLOGICAL.
Genetic Mutations that Lead to Chronic Myelogenous Leukemia: Causes and Treatments Marty O’Neill II & Carmen Banea
Here are some CML slides that may be helpful for your presentation.
Which has the Human Genome Project most improved in the field of medicine? A. the ability to generate vaccines B. the diagnosis and treatment of disease.
23.1 Cancer Is a Group of Diseases Characterized by Cell Proliferation.
1 Genomics and the Human Condition Francis S. Collins, M.D., Ph.D. Dedication of Ken Olsen Science Center Gordon College September 27, 2008.
Interesting Developments. Historic trends in biotech fields.
Chronic Myelogenous Leukemia By: Bobby Orr Danielle Heinbaugh Adam Edwards.
Case Study MICR Hematology Spring, 2011 Case # 5 Hee Jin Kim, Hooman Nikizad and Arthur Omuro.
CANCER Chapter 26 (3th edition) Chapter 24 (3th edition)
hyperproliferation of white blood cells
PERSONALIZED MEDICINE AND IT’S RELEVANCE TO CANCER PATIENTS Casey Scarelli, Sallyann Vu, Jess Soule, Abrar Ahmed, Alief Imam.
Molecular Monitoring in CML the process and questions we can answer Letizia Foroni.
Bio 328 Immunology Cancer and the Immune System.
Molecular Modeling 1. Introduction to Computational Molecular Physics 2. Molecular Mechanics 3. Conformation Searching 4. Molecular Orbital Methods 5.
Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.
TSC1 and Facial Angiofibromas
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis.
Heterogeneous group of hematopoietic neoplasms Uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation Composed.
Cancer Genome Landscapes
What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of.
Comment on “Chromosomal Instability and Tumors Promoted by DNA Hypomethylation” and “Induction of Tumors in Mice by Genomic Hypomethylation” by Allen S.
ONCOGENE AND ITS ROLE IN THE DEVELOPMENT OF LEUKAEMIA Nouf khaled al-Hajjar SUPERVISOR Dr.SAMINA HAQ.
Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.
Nada Mohamed Ahmed, MD, MT (ASCP)i. Objectives chronic myeloid leukaemia (CML) Haematopoietic malignancies Polycythemia vera (PV) Idiopathic myelofibrosis.
Karyotyping Cancer.
Regulation of Cell Division and Cancer
Naomi Fujioka, MD, Christopher A. French, MD, Michael J
CLINICAL PROGRESSION INTRODUCTION METHOD CONCLUSION REFERENCES
Chronic myelogenous leukemia (CML)
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy  Stefania Aliano, Gabriella Cirmena, Giuseppina.
CHRONIC MYELOID LEUKEMIA (CML)
Assistant Prof. Dr. Nibras Saleam Al-Ammar PhD in Clinical Immunology
Controls the Cell Cycle
Leukemia Human Disease Asma Siddique BIOT 412.
RNA Identity Crisis: Hepatitis B Walks the LINE
Genetics Of Cancer Regulation of cell proliferation and cancer
Chapter 17: Regulation of cell number
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Oncogenes and tumour suppressor genes
Notch1 and its role in pre-T-cell acute lymphoblastic leukemia (T-ALL)
Extracellular Regulation of Apoptosis
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Fig. 6. Pathway analysis of CMLD
Table 1. Laboratory data on admission
MicroRNAs: From Decay to Decoy
A Genetic Screen for Candidate Tumor Suppressors Identifies REST
A New FOXO Pathway Required for Leukemogenesis
aMAGEing New Players Enter the RING to Promote Ubiquitylation
CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST
The Pathway to Progress Against Chronic Myelogenous Leukemia.
Presentation transcript:

Finding Cancer Genes

CML: Chronic Myelogenous Leukemia – Asymptomatic at time of diagnosis Abnormal white blood cell count Stable for 3 – 5 years followed by “Blast Crisis” Fatal within 3 – 6 months of Blast crisis 20% of all leukemia's 5000 cases per year in US (compare with 180,000 lung cancer cases)

Finding Cancer Genes CML: Chronic Myelogenous Leukemia – All CML cells harbor Philadelphia chromosome 1960: Peter Nowell David Hungerford Nowell P, Hungerford D. "A minute chromosome in chronic granulocytic leukemia." Science 1960;132:1497.

Finding Cancer Genes 1973: Janet D. Rowley Discovered t(9;22) Rowley JD. "A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]". Nature 1973;243:290–3.

Finding Cancer Genes

Bcr-Abl

Non-physiological Activation of Bcr-Abl Activation of Signaling

c-Abl – Physiological Roles c-Abl is a nuclear-shuttling protein that regulates p53

c-Abl – Physiological Roles

c-Abl Kinase Domain Structure

STI-571

Parametric Linkage analysis

3

Fig. 1. The β-catenin protein interaction network. Michael B. Major et al. Science 2007;316: Published by AAAS

Fig. 3. WTX promotes β-catenin ubiquitination and degradation. Michael B. Major et al. Science 2007;316: Published by AAAS

Tumour Suppressors Example 4: REST

Thomas F. Westbrook, Eric S. Martin, Michael R. Schlabach, Yumei Leng, Anthony C. Liang, Bin Feng, Jean J.... A Genetic Screen for Candidate Tumor Suppressors Identifies REST Cell, Volume 121, Issue 6, 2005,